Board and Management

Board and Management

The Board of Directors is ultimately responsible for the strategy and organisation, as well as the management of operations. The Board appoints the CEO, who is responsible for managing the day-to-day operations in accordance with guidelines from the Board.

Board

Board

The Annexin Board of Directors is comprised of a number of experienced individuals that together have a wide range of expertise within various aspects of pharmaceutical development, such as investments, acquisitions, licensing, product launch, and marketing.

Jan Nilsson

Chairman of the Board since 2024

Born: 1949
Nationality: Swedish

Education and professional experience: Jan Nilsson holds a M.Sc. from the University of Gothenburg and an MBA from Uppsala University. Jan has long and broad experience from both large pharmaceutical companies and biotech firms. He has been active in several different therapeutic areas in the pharmaceutical industry and has, in addition to participating in the product development process, also had key roles in the launch, sales and marketing of established international brands. Jan also has solid management background, having served as CEO in both public and private companies.

Other assignments: Jan is currently Chairman of the Board of CCRM Nordic AB (svb) and a member of the Board of Directors of Aptahem AB (publ), CarryGenes Therapeutics AB and Urbicum Ledningskonsult AB.

Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders.
Shareholding in the Company: No shares

Mikael Lönn

Member of the Board since 2024

Born: 1949
Nationality: Swedish

Education and professional experience: Mikael is a M.Sc. and physician with extensive experience as a business leader and entrepreneur, primarily in the healthcare sector. He has extensive experience in financial investments and solid experience from advising and actively engaging with the board of directors in a number of start-up and growth companies as well as experience from large county council and municipal-owned organizations.

Other assignments: Today, Mikael has board assignments in several companies, including Chairman of the Board of Wingspan Company Culture AB, Dentalum Operations AB and Dentalum Group AB and Board member of Genovis AB (publ), Oxlantic Medical AB, Redeye AB/Redhold AB, Vasa Angels 1 AB, Mikael Lönn AB, Professional Corporate Governance in Sweden AB, Professional Corporate Governance PÄAB ll, and Collabodoc AB.

Independent: Mikael has been a shareholder in Annexin Pharmaceuticals since 2016. Mikael is not independent in relation to the company, its management or major shareholders. Mikael Lönn is the largest shareholder with 26.0 percent ownership in Annexin Pharmaceuticals AB.

Shareholding in the Company: 138 405 749 shares

Carl-Fredrik Lindner

Member of the Board since 2017

Born: 1976
Nationality: Swedish

Education and professional experience: Carl-Fredrik Lindner has a Master of Science from KTH Royal Institute of Technology, Stockholm, Sweden. He has a background in Corporate Finance and worked with a Venture Capital fund, investing in Life Science.
Other assignments: Investment Manager at Lionpeak AB, Stockholm, Sweden.

Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders.
Shareholding in the Company: 1 040 005 shares

Mikael von Euler

Member of the Board since 2023

Born: 1953
Nationality: Swedish

Education and professional experience: Mikael von Euler is a licensed physician with a PhD from Karolinska Institutet. Von Euler is a trained oncologist with more than 30 years of experience from the pharmaceutical industry. He was previously Senior Vice President and CMO of Aprea Therapeutics, CMO of KDevOncology, Akinion, Axelar and Oncos Therapeutics (now Targovax). He has held several senior positions within the global organization of large pharmaceutical companies, including Cluster Head of Roche/Genentech, Vice President of GlaxoSmithKline and Global Product Director of AstraZeneca.
Other assignments: Board member of Dicot AB.

Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders.
Shareholding in the Company: 240 000 shares

Management

Management

The management team of Annexin Pharmaceuticals has a long experience within the area of research and development of pharmaceutical products; from preclinical stage to market authorisation application, including mergers, acquisitions and licensing.

Anders Haegerstrand

Chief Executive Officer

Born: 1961
Nationality: Swedish
Position: Board member 2018-2020, Chief Executive Officer since 2019

Education and professional experience: Anders Haegerstrand has extensive R&D experience including drug discovery and development as manager at Karolinska Institutet, Astra Pain Control AB and AstraZeneca LLC and within biotech. From year 2000, Anders was CEO and CSO for NeuroNova AB, a leading company in applied stem cell research that brought to protein molecules into Phase I/II clinical studies. The company was later acquired by a listed company, Newron Pharmaceuticals S.p.A., at which Anders was a management team member between 2013 and 2016.

Shareholding in the Company: 1 834 863 shares and 300 000 share option rights serie 2022/2025

 

Anna Frostegård

Chief Scientific and Medical Officer

Born: 1973
Nationality: Swedish
Position: Co-founder and inventor since 2014. Chief Scientific and Medical Officer since 2016.

Education and professional experience: Anna Frostegård, MD, PhD, Licensed Physician, is a globally educated Licensed Physician who earned her Doctor of Medicine degree summa cum laude and earned her Doctor of Philosophy degree in Experimental Medicine from Karolinska Institutet. She has served as an Assistant Professor at the Unit of Immunology and Chronic Disease and has more than 10 years’ experience in translating academic discoveries into the development of biological drugs. Anna is one of the inventors and co-founder of Annexin Pharmaceuticals and is an expert in Annexin A5, vascular inflammation and cardiovascular diseases.

Shareholdings in the Company: 8 791 546 shares indirectly through Medirista AB and 150 000 share option rights serie 2022/2025

Susan Suchdev

Chief Operating Officer

Born: 1972
Nationality: Swedish
Position: Chief Operating Officer since 2018

Education and professional experience: Susan Suchdev has a M.Sc. from Karolinska Institutet in Stockholm. Earlier she had the position as COO at Klaria Pharma and has previously had a long career with management roles in clinical development projects, including Pfizer, TFS Trial Form Support and Nestlé Health Science.

Shareholding in the Company: 288 126 shares and 150 000 share option rights serie 2022/2025. 168 000 shares via related parties.

Susanne Andersson

Chief Financial Officer

Born: 1971
Nationality: Swedish
Position: Chief Financial Officer since 2023

Education and professional experience: Susanne Andersson holds a Bachelor of Business Administration from College of Charleston, S.C. USA. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines as well as financial management positions, including investor relations at Ericsson within the telecom industry.

Shareholding in the Company: No shares.

Therapeutic Area Heads

Therapeutic Area Heads

Mario Fsadni

Therapeutic Area Head Ophthalmology

Position: Therapeutic Area Head Ophthalmology at Annexin since 2022

Education and professional experience: Mario Fsadni, MBChB, MRCOphth, MSc, LLM, FMH, obtained his Medical Degree and Ophthalmology training in Manchester, UK. He brings experience gained over several years of ophthalmic drug development. He was previously the Global Medical Director at Novartis Ophthalmics and Director Product Development (Ophthalmology) at Allergan, before starting a consultancy designed specifically for the development of pharmaceutical products for ophthalmic disorders. Mario has had an active part in projects spanning all sub-therapeutic areas in ophthalmology, sixteen of which have had successful global marketing approval.

Shareholdings in the Company: No shares. 200 000 share option rights serie 2022/2025.

Alain Thibault

Therapeutic Area Head Oncology

Position: Therapeutic Area Head Oncology since 2023

Education and professional experience: Alkain Thibault obtained his Medical Degree at McGill University Montreal, Canada and Board Certification in Oncology and Internal Medicine in the US. He has held management and specialist positions at Roche, J&J and Regeneron as well as Chief Medical Officer roles in biotech companies. Alain has as a medical oncologist extensive global experience leading novel compounds through clinical development.

Shareholdings in the Company: No shares